Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).

被引：2
|
作者：
Veccia, Antonello
Burgio, Salvatore Luca
Di Lorenzo, Giuseppe
Ortega, Cinzia
Scognamiglio, Florinda
Aieta, Michele
Zustovich, Fable
Mattioli, Rodolfo
Mansueto, Giovanni
Facchini, Gaetano
Procopio, Giuseppe
D'Angelo, Alessandro
Spizzo, Gilbert
Donini, Maddalena
Bortolus, Roberto
Vicario, Giovanni
Zucali, Paolo A.
Basso, Umberto
Lo Re, Giovanni
Caffo, Orazio
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[3] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[4] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[5] Cardarelli Hosp, Neaples, Italy
[6] IRCCS CROB Ctr Riferimento Oncol Basilicata, Rionero In Vulture, Italy
[7] Veneto Inst Oncol IRCCS, Padua, Italy
[8] Santa Croce Hosp, Med Oncol Unit, Fano Pu, Italy
[9] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[10] NCI Pascale Fdn, Neaples, Italy
[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[12] Civil Hosp, Taormina, Italy
[13] Civil Hosp, Merano, Italy
[14] Ist Ospitalieri Cremona, Cremona, Italy
[15] Natl Canc Ctr CRO, Aviano, Italy
[16] Osped San Giacomo Apostolo Med Oncol, Castelfranco Veneto, Italy
[17] Humanitas Canc Ctr, Rozzano, Italy
[18] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[19] Santa Maria Angeli Gen Hosp, Pordenone, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?
    Kongsted, Per
    Svane, Inge Marie
    Lindberg, Henriette
    Daugaard, Gedske
    Sengelov, Lisa
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (11) : 494.e15 - 494.e20
  • [33] Use of plasma androgen receptor (AR) testing to optimize docetaxel chemotherapy in castration-resistant prostate cancer (CRPC): A multicenter biomarker study.
    Conteduca, Vincenza
    Castro, Elena
    Wetterskog, Daniel
    Scarpi, Emanuela
    Romero-Laorden, Nuria
    Gurioli, Giorgia
    Jayaram, Anuradha
    Lolli, Cristian
    Schepisi, Giuseppe
    Wingate, Anna
    Casadei, Chiara
    Lozano, Rebeca
    Brighi, Nicole
    Aragon, Isabel
    Marin-Aguilera, Mercedes
    Gonzalez-Billalabeitia, Enrique
    Mellado, Begona
    Olmos, David
    Attard, Gerhardt
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
    Buttigliero, Consuelo
    Pisano, Chiara
    Tucci, Marcello
    Vignani, Francesca
    Bertaglia, Valentina
    Iaconis, Davide
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    ACTA ONCOLOGICA, 2017, 56 (04) : 555 - 562
  • [35] Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto)
    Danila, D. C.
    de Bono, J.
    Ryan, C. J.
    Denmeade, S.
    Smith, M.
    Taplin, M.
    Bubley, G.
    Molina, A.
    Haqq, C.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Clinical implications of intraductal carcinoma of the prostate sub-patterns in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel as the first-line therapy
    Zhipeng, W.
    Zhu, S.
    Chen, J.
    Zhao, J.
    Zhang, X.
    Sun, G.
    Chen, N.
    Zeng, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S529 - S529
  • [37] A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide Versus Docetaxel as First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer-CHEIRON Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 12 - 12
  • [38] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)
    Fontana, A.
    Bocci, G.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Santini, D.
    Landi, L.
    Bursi, S.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel
    Oudard, Stephane
    Sengelov, Lisa
    Mainwaring, Paul N.
    Thiery-Vuillemin, Antoine
    Theodore, Christine
    Kulikov, Evgeny
    Yachnin, Jeffrey
    Kocak, Ivo
    Kataja, Vesa V.
    Luukkaa, Marjaana
    Nosov, Aleander
    Hjelm-Eriksson, Marie
    Bubis, Jeffrey
    Shen, Liji
    Risse, Marie-Laure
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345